Gastroesophageal varices bleeding is a major complication in patients with cirrhosis. Gastric varices (GVs) occur in approximately 20% of patients with portal hypertension. However, GV bleeding develops in only 25% of patients with GV and requires more transfusion and has higher mortality than esophageal variceal (EV) bleeding. The best strategy for managing acute GV bleeding is similar to that of acute EV bleeding, which involves airway protection, hemodynamic stabilization, and intensive care. Blood transfusion should be cautiously administered in order to avoid rebleeding. Vasoactive agents such as terlipressin or somatostatin should be used when GV bleeding is suspected. Routine use of prophylactic antibiotics reduces bacterial infection and lowers rebleeding rates. By administering endoscopic cyanoacrylate injection, the initial hemostasis rate achieved is at least 90% in most cases; the average mortality rate of GV bleeding is approximately 10e30% and the rebleeding rate is between 22% and 37%. Although endoscopic injection of cyanoacrylate is superior to sclerotherapy and band ligation, and has remained the treatment of choice for treating acute GV bleeding, the outcome of this treatment is still unsatisfactory. New treatment options, such as thrombin injection, transjugular intrahepatic portosystemic shunts, or balloon-occluded retrograde transvenous obliteration, have shown promising results for acute GV bleeding. However, randomized controlled trials are needed to compare the efficacy of these therapies with cyanoacrylate.
Introduction
Gastroesophageal varices (GOVs) bleeding is a major complication in patients with cirrhosis. Gastric varices (GVs) are less common than esophageal varices (EVs), occurring in approximately 20% of patients with portal hypertension. 1 The GV bleeding occurs in approximately 25% of patients with GV, which is lower than EV bleeding. 1, 2 Although the prevalence and bleeding risk of GV are lower, the bleeding is usually more severe, requires more transfusions, and is associated with higher mortality than EV bleeding. 1, 3 Even after administering a standard endoscopic injection of tissue glue, GV bleeding is still associated with high rebleeding rates, ranging from 22% to 37%. 4e7 The prognosis of patients with EV bleeding has improved over the past few decades, 8e10 whereas the clinical outcome of GV bleeding is still far from satisfactory. The optimal treatment of acute GV bleeding remains controversial, but a multidisciplinary approach, including pharmacological agents, endoscopic treatment, and radiological interventions, has been suggested. This review provides an outline of the portal hemodynamics, pathophysiology, and classification of GV, and finally focuses on the currently available treatment modalities for acute GV bleeding based on the recent studies.
Classification of GVs
At present, the most widely accepted classification of GVs is the Sarin classification (Fig. 1) . 1 The GOVs are GVs that extend beyond the esophagealecardiac junction and are associated with EVs. Isolated GV (IGVs) are GVs without concomitant EVs. The GOVs are further classified as (1) type 1 GOVs (GOV1), which are the continuation of EVs and extend for 2e5 cm below the esophagealecardiac junction, along the lesser curvature side of the stomach; (2) type 2 GOVs (GOV2) are those extending into the gastric fundus. The IGVs are also subclassified into two groups, namely, type 1 IGVs (IGV1), which are the isolated varices in the gastric fundus and are also called fundal varices, and type 2 IGVs, which are ectopic varices that appear in any location of the stomach except the fundus.
Hemodynamics of portal hypertension
Portal hypertension is the combined result of an increase in both portal blood flow and intrahepatic vascular resistance. 11 Normally, blood from the splenic vein and the superior mesenteric vein drains into the liver through the portal vein system. In intrahepatic portal hypertension (such as cirrhosis), the portal blood flow to the liver is decreased and shifted into two main venous pathways due to an increase in intrahepatic vascular resistance. First, the right/left gastric veins usually drain into the distal esophagus and the cardia, forming EVs and GOV1. 12 Second, the short/posterior gastric veins usually drain into the fundus and form fundal varices (GOV2 and IGV1). 12 The IGV2 is formed by dilatation of branches from the gastroepiploic veins. 13 Different from EVs, GVs are usually associated with spontaneous splenorenal or gastrorenal shunts (GRSs).
12 These shunts, collectively described as GRSs, usually connect through the inferior phrenic or suprarenal vein to the left renal vein. 12 Approximately 60e85% of GVs are associated with GRS, in comparison with 17e21% of EVs. 12, 14 Previous studies have shown that the portal pressure of GVs is lower than that of EVs. 12, 15 The GRS might provide an additional pathway for portal blood flow, and thus lower the portal pressure in GVs associated with GRS.
Management of acute GV bleeding

Initial resuscitation and general management
Endotracheal intubation to provide airway protection before endoscopy and prevention of aspiration in case of massive ongoing bleeding or altered mental status may be necessary. Maintaining hemodynamic stability and preserving tissue perfusion are the main goals of resuscitation. Consequently, cautious blood transfusion should be promptly initiated with a target hemoglobin level between 7 and 8 g/dL. 16 Results of an animal study showed that the replacement of all lost blood induces an increase in portal pressure and is associated with higher rebleeding and mortality. 17 Management of coagulopathy and thrombocytopenia could not be established due to the lack of sufficient evidence. In addition, a recent randomized controlled trial does not support the use of recombinant factor VIIa for variceal bleeding. 18 Limited studies are available on the efficacy of vasoactive agents (such as somatostatin, terlipressin, or octreotide) in controlling acute GV bleeding. Based on the similar pathophysiology of portal hypertension, it is not unreasonable to administer these agents in acute GV bleeding. Vasoactive agents should be administered as soon as possible (before endoscopy) when variceal bleeding is suspected. 16 The current medical consensus recommends using these agents for up to 5 days after endoscopic treatment. 16 Bacterial infection is reported in more than 50e60% of cirrhotic patients with gastrointestinal bleeding and associated with increased risk of rebleeding.
19e23 Antibiotic prophylaxis has been proven to reduce bacterial infection and rebleeding in such patients. 19,20,23e25 Thus, antibiotic prophylaxis should be instituted from admission in all patients with cirrhosis and upper gastrointestinal bleeding. 16 The antibiotic of choice for most patients is oral quinolone (e.g., 400 mg norfloxacin administered 2 times daily for 7 days orally). 16 Intravenous ceftriaxone is a demonstrated alternative and may be more effective for area with increasing quinolone resistance and more frequent Gram-positive bacterial infections. 16, 26 A recent randomized controlled trial with limited patient numbers first demonstrated a beneficial effect of lactulose for the prevention of hepatic encephalopathy in patients with cirrhosis and acute variceal bleeding. 27 Fourteen percent (5/35) of patients receiving routine lactulose treatment (30 mL 3e4 times/day) developed hepatic encephalopathy; this was in contrast with 40% (14/35) of patients receiving placebo had hepatic encephalopathy after acute variceal bleeding. 27 However, further large randomized controlled trials are necessary before recommending routine lactulose treatment in variceal bleeding.
Balloon tamponade
Balloon tamponade should only be used in circumstances involving massive bleeding as a bridge therapy until more definitive therapy can be provided, 16 and the maximal duration of use is 24 hours. Currently, limited sources are available on balloon tamponade for GV bleeding. The initial hemostasis rate of balloon tamponade for EV bleeding is approximately 80e90%, but permanent hemostasis is only 58%. 28 A previous study reported that 24% of patients developed complications (fatal in 5% of cases), which increased with the duration of use. 28 Because of its larger gastric balloon capacity (600 mL), LintoneNachlas tube is increasingly the preferred tube of choice for GV bleeding than the SengstakeneBlakemore tube.
Endoscopic therapy
Sclerotherapy
Injection of sclerosants such as ethanolamine oleate, absolute alcohol, or tetradecyl sulfate (administered intravariceally or perivariceally) causes endothelial damage, thrombosis, and sclerosis of the varix. However, the higher volume of blood flow in GV results in rapid flushing of the sclerosant in the bloodstream. Thus, sclerotherapy for GV usually requires larger volumes of sclerosants than EV, which are associated with increased side effects. 29 The initial hemostasis rate of sclerotherapy for acute GV bleeding ranged between 67% and 100%.
29e32 However, a very high rebleeding rate of up to 90% was reported as well. 29e32 The eradication rates of GVs were from 40% to 95%, depending on the types of GVs. 29, 30 Complication rates after a sclerotherapy for GV bleeding varied from 24% to 82%. 5, 30 The commonly reported complications after a sclerotherapy are dysphagia, retrosternal pain, abdominal pain, fever, and ulcerations.
Considering the unacceptably high rebleeding and complication rates, and only average initial hemostasis ability, sclerotherapy is not recommended as the first-line treatment for GV bleeding.
Variceal band ligation
Although band ligation had been established as the standard treatment for EV bleeding, it has a limited ability to control GV bleeding. A number of case series initially showed that band ligation is a safe and effective treatment for acute GV bleeding.
33e36 However, two later randomized controlled trials comparing band ligation with cyanoacrylate injection demonstrated that band ligation had lower initial hemostasis and higher rebleeding rates. 6, 37 The 2-and 3-year cumulative rebleeding rates were as high as 63% and 72% for patients undergoing band ligation compared with cyanoacrylate injection (27% for both periods). 6 Thus, variceal band ligation could be considered as an alternative modality for acute GV bleeding if cyanoacrylate is not available at the time of treatment. In addition, band ligation could be used as the first-line therapy if the bleeder is GOV1. 16 However, concerning the lower hemostasis and higher rebleeding rates of band ligation, further definitive treatment should be provided for secondary prophylaxis after patients are stabilized initially.
GV obturation
The GVobturation (GVO) refers to the injection of agents such as N-butyl-2-cyanoacrylate (Histoacryl) or isobutyl-2-cyanoacrylate (bucrylate), which induce solidification and thrombosis in the varix. 13 Endoscopic injection of cyanoacrylate for treating EVs was first reported by Gotlib and Zimmermann. 38 Later, Soehendra et al described its first use for treating GVs. 39 Since then, cyanoacrylate had gradually become a widespread treatment modality for acute GV bleeding. 4e7, 37,40e45 In most series, the initial hemostasis by cyanoacrylate is at least 90%. 5e7, 42, 43 The rebleeding rate of GVO is approximately 22e37%. 4e7 The GVO is more effective in achieving variceal obturation, with a higher initial hemostasis and less need for surgery than sclerotherapy. 5, 40 A prospective nonrandomized cohort study also showed survival benefit of GVO when compared with sclerotherpay. 40 As previously mentioned, GVO is superior to band ligation for acute GV bleeding with higher initial hemostasis and lower rebleeding rates. 6, 37 A randomized controlled trial demonstrated higher cumulative survival rate of GVO than band ligation. 37 Common complications associated with GVO are pyrexia and abdominal pain/discomfort. Severe complications after GVO are mostly associated with systemic thromboembolic phenomena such as cerebral, pulmonary, portal vein, and splenic infarction. Because of its high efficacy in arresting acute hemorrhage and less rebleeding than sclerotherapy and band ligation, GVO is recommended as the treatment of choice for acute GV bleeding. 16 
Thrombin injection
Thrombin plays a role in converting fibrinogen into fibrin clot and promotes platelet aggregation. 50 Thrombin was first used for acute gastric hemorrhage in 1947. 51 Since then, it was widely used for hemostasis in surgical procedures. A number of small case series using thrombin or fibrin glue (a mixture of human fibrinogen, factor XIII, and human thrombin) for acute GV bleeding were reported. 50,52e56 The advantage of thrombin injection is the absence of postinjection ulcer at the puncture site. 52 Theoretically, the rebleeding rate should be lower in the absence of ulcer formation. In most studies, the initial hemostasis rate is over 90%, the rebleeding rate is between 0% and 28%, and the mortality rate is from 0% to 50%.
Several previous studies used bovine thrombin for injection. 52, 53 However, ongoing concerns about bovine thrombin associated with spongiform encephalopathy and CreutzfeldteJakob syndrome should be noted. Consequently, human thrombin was more widely used than bovine thrombin in later studies. 50, 54, 55 Although initial case series showed promising results of thrombin injection for GV bleeding, the current evidence is not sufficient to recommend thrombin as a standard treatment. Further randomized controlled trials comparing thrombin with cyanoacrylate are needed.
Radiologic intervention
Transjugular intrahepatic portosystemic shunts
Currently, the endoscopic treatment of choice for acute GV bleeding is GVO. However, the rebleeding rate of GVO remains high. When patients with GV bleeding are unresponsive to initial endoscopic treatment, a second endoscopic therapy should be attempted if possible. 16 If a second attempt fails or the severity of bleeding precludes further endoscopic therapy, salvage therapy using surgical shunts or transjugular intrahepatic portosystemic shunts (TIPSs) should be considered for refractory GV bleeding. Because most patients undergoing rescue therapy have advanced liver disease with high surgical risk, TIPS is usually the first choice for salvage therapy.
Most current studies of TIPS focus on treatment for refractory GV bleeding and prevention of GV rebleeding. However, limited sources describing the role of TIPS for acute GV bleeding are available. A recent study showed that the primary hemostasis rate of TIPS for acute GV bleeding is 92.3%. 57 Other studies showed initial hemostasis of TIPS for acute refractory GV bleeding is between 87% and 100%, 58e62 with an approximate rebleeding rate of 10e30%. 58e63 In a recent randomized controlled study with a small case number, TIPS was more effective than GVO in preventing GV rebleeding. 64 Frequent complications of TIPS are encephalopathy and shunt stenosis/occlusion, with post-TIPS encephalopathy occurring in 4e16% of patients. 61e63 The 5-year cumulative probability of encephalopathy is up to 50%. 63 Shunt stenosis/ occlusion develops in 18e82% of patients who underwent TIPS. 65, 66 This high rate of shunt dysfunction could be reduced by using polytetrafluoroethylene (PTFE)-covered stent. 67, 68 An expanded cost analysis showed that there was no overall difference between TIPS and surgical shunts over a 5-year postsurgical period. 63 However, the cost-effectiveness analysis showed that TIPS had higher total costs than GVO in the 6e12-month follow-up period. 44, 69 Although a recent randomized controlled trial showed early TIPS (within 72 hours) reduced treatment failure and mortality in high-risk patients (Child B with active bleeding or Child C) with EV bleeding, 70 its role in acute GV bleeding needs further investigation.
Considering the currently available evidence, TIPS with PTFE-covered stent is the treatment of choice for patients who failed first-line medical and endoscopic therapy. 16 
Balloon-occluded retrograde transvenous obliteration
As previously mentioned, 60e85% of GVs are associated with GRS. 12, 14 The GRS drains blood flow into systemic circulation and provides a pathway for radiologists to treat GV. Kanagawa et al first introduced the balloon-occluded retrograde transvenous obliteration (BRTO) procedure in 1996, in which a balloon catheter was inserted into the left adrenal vein through the left renal vein by either the transjugular or transfemoral approach. 71 The outflow of GRS was blocked by inflating the balloon, and 5% ethanolamine oleate iopamidol was injected in a retrograde manner (Fig. 2) . The BRTO was used as either primary or secondary prophylaxis of GV in most series. However, few nonrandomized comparative studies with small patient numbers reported its application for acute GV bleeding. 57, 72, 73 Initial hemostasis of BRTO for acute GV bleeding ranges between 76.9% and 100%. 57, 72, 73 It was noted that the rebleeding rate was from 0% to 15.4%. 57, 72, 73 In two small series, BRTO had a similar initial hemostasis and lower rebleeding rate, compared with GVO or band ligation for acute GV bleeding. 72, 73 The BRTO had been shown to be as effective as TIPS for acute GV bleeding, without increasing hepatic encephalopathy. 57 The BRTO had been shown to increase portal blood flow, resulting in improved liver functions. 57, 74, 75 However, portal pressure also increased significantly after BRTO, which caused worsening of EV. 14, 74, 75 Other common complications of BRTO are hemoglobinuria, abdominal pain, pyrexia, and pleural effusion. 13 Major complications are shock and atrial fibrillation. The worsening of EV is an important long-term issue. Further randomized controlled trials comparing BRTO with TIPS or GVO for acute GV bleeding are needed.
Liver transplantation
The GVs bleeding is one of the manifestations of decompensated cirrhosis. Liver transplantation is the curative treatment option for cirrhosis and has been proposed as an option for bleeding EVs.
76e78 To date, however, there are no randomized trials of liver transplantation for either acute EV or GV bleeding. In addition, the application of liver transplantation for acute GV bleeding is limited due to donor shortage and prolonged waiting time. Thus, current consensus recommends that liver transplantation could be considered in patients who fail endoscopic and pharmacological treatment for the prevention of rebleeding. 16 The TIPS procedure could be used as a bridge to liver transplantation.
Future perspectives
It is never enough to just pursue a better clinical outcome of acute GV bleeding. Head-to-head comparisons between different endoscopic and radiological modalities for acute GV bleeding are desperately needed. Furthermore, combination treatment of these modalities might also be a way to improve outcomes or decrease complications of acute GV bleeding.
In conclusion, primary GV occurs in approximately 20% of patients with portal hypertension. The average bleeding risk of patients with GV is approximately 25%; however, individual risks of bleeding depend on different types of GV classification, liver functions, red color signs, and the size of GV. The GV bleeding requires more blood transfusion and has higher mortality than EV. Current standard treatment for fundal GV bleeding is GVO. It has been demonstrated that band ligation could be used as the first-line therapy for bleeding due to GOV1. Other treatment modalities (especially radiologic interventions) have shown promising outcomes for acute GV bleeding, but their long-term complications need further evaluations. Table 1 4e7,12,13,28e31,32e36,41,42,49,51e55,56e65,69e73 summarizes the outcomes of currently available treatment modalities for acute GV bleeding. In addition, we proposed a management algorithm for acute GV bleeding in Fig. 3 . In conclusion, management of acute GV bleeding includes timely initial resuscitation, cautious blood transfusion, pharmacological therapy, prophylactic antibiotics, and urgent endoscopic treatment (within 12 hours). If therapeutic endoscopy fails to control bleeding, a salvage radiologic intervention should be considered.
